Skip to main content

Table 1 Baseline demographic characteristics and outcome measures

From: The effect of choline-stabilized orthosilicic acid in patients with peri-implantitis: an exploratory randomized, double-blind, placebo controlled study

Variable

Treatment group

p value

Placebo

CS-OSA

Number of patients

10

8

 

Number of implants

20

16

 

Age

51.50 ± 10.19

52.50 ± 7.29

0.818

Number of males

3

5

0.168

PPD (mm)

5.04 ± 2.37

6.01 ± 2.54

0.009

REC (mm)

0.78 ± 1.27

0.70 ± 1.22

0.577

BOP (%)

86.67 ± 34.14

94.79 ± 22.34

0.045

IS-AC (mm)#

2.57 ± 2.56

2.4 ± 2.19

0.765

IS-BIC (mm)#

3.83 ± 2.39

4.43 ± 1.98

0.467

OHIP Total

15.10 ± 10.81

14.63 ± 8.35

0.515

hsCRP (mg/L)

2.40 ± 2.40

4.12 ± 2.83

0.055

Osteocalcin (ng/mL)

9.04 ± 3.39

9.88 ± 3.67

0.762

BAP (µg/L)

10.22 ± 4.20

10.13 ± 1.58

0.203

CTX-I (ng/mL)

0.48 ± 0.22

0.52 ± 0.23

0.696

PINP (ng/mL)

43.35 ± 12.61

47.03 ± 8.51

0.573

  1. Data expressed as mean ± SD. Significant difference between groups: p < 0.05 = significant (bold) #IS-AC and IS-BIC analysis was performed on cone beam computed tomography (CBCT) scans of sufficient quality (i.e. without artefacts) taken from 9 patients (19 implants) in the placebo group and 6 patients (7 implants) in the CS-OSA group. CS-OSA: choline-stabilized orthosilicic acid, PPD: probing pocket depth, REC: mucosal recession, BOP: bleeding on probing, IS-AC: distance from implant shoulder to alveolar crest, IS-BIC: distance from implant shoulder to first bone-to-implant contact, OHIP: patient’s oral health related quality of life questionnaire, hsCRP: high sensitive C-reactive protein, BAP: bone alkaline phosphatase, CTX-I: C-terminal telopeptide of collagen I, PINP: N-terminal propeptide of type I procollagen